Company news

Share this article:

PDI has inked a deal with an undisclosed "top-five pharmaceutical company" that is expected to generate $23 million in revenue for the contract sales firm over its one-year term. The deal will target primary care physicians and specialty audiences, PDI said. News of the deal comes just three months after PDI began work for another unnamed pharma company, marketing its cardiology drug to primary care doctors and cardiologists. That deal is expected to generate $13 million in revenue for PDI.Both recent sales agreements have been considered welcome news by PDI since they have helped the firm regain ground following a string of contract losses that began in 2006. PDI had endured four major contract losses, including the termination of $35 million deal that was previously expected to be extended through the end of 2007, prior to signing new deals in March and July.

Santarus said its sales reps will commence promotional activities in the third quarter for Victory Pharma's Naprelan (naproxen sodium) brand products under a recent co-promotion agreement. Naprelan tablets are a once-daily control-release formulation of the non-steroidal anti-inflammatory drug (NSAID) naproxen sodium, indicated for pain relief caused by a number of conditions including arthritis. Santarus said it plans to have its sales reps promote Naprelan to targeted primary care physicians. The initial focus of Santarus' promotional efforts will be on the 375 mg dosage strength on Naprelan. Santarus reps promoting Naprelan will also continue to sell Zegerid (omeprazole/sodium bicarbonate) brand products to targeted gastroenterologists and primary care physicians. Zegerid is also sold by field reps from inVentiv and Otsuka America.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Avastin pockets another Priority Review label

It's the second for this cancer drug in two weeks.

Court invalidates some healthcare subsidies

The lawsuit has been wending its way through the courts for a while, and, although it is being deliberated in several other venues, the decision is part of a legal dispute that puts patients in the 36 states offering federal exchanges in limbo.

FDA generic division overhaul kicks in

The Food and Drug Administration has been intent on elevating and reorganizing its office of Generic Drugs since 2012.